New combination for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new combination treatment (ubamatamab plus another drug) for people with ovarian cancer that no longer responds to platinum chemotherapy. It could be an option if your cancer has kept growing despite prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a specific type of ovarian, fallopian tube, or primary peritoneal cancer (not clear cell, mucinous, or carcinosarcoma).
- Your cancer must have gotten worse after previous treatment, and you need to have at least one measurable tumor that hasn't been treated with radiation.
- You should be in fairly good health, able to care for yourself and do light activities (ECOG 0 or 1).
- Your liver, kidneys, and bone marrow must be working well enough as determined by your doctor.
- You cannot have had major surgery or a serious injury in the last 4 weeks, or have untreated infections, active brain tumors, or a bowel obstruction in the last 3 months.
- You must not have had a severe allergic reaction to antibody treatments or doxorubicin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug, ubamatamab, to standard chemotherapy for advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if this combination is safe and effective.
This Phase 1/2 study tests how safe REGN5668 is and how well it works in adult women with advanced gynecologic cancers. It compares REGN5668 given with cemiplimab alone, or cemiplimab plus fianlimab, and looks for responses in tumors that meet specific criteria.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
This study tests a new drug (BG-C9074) combined with a standard targeted therapy (bevacizumab) for women newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding this new drug can help shrink or control the cancer better than the standard approach alone.
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.